Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Corvus Pharmaceuticals (CRVS) Receivables - Other (2022 - 2024)

Corvus Pharmaceuticals has reported Receivables - Other over the past 3 years, most recently at $70000.0 for Q3 2024.

  • Quarterly results put Receivables - Other at $70000.0 for Q3 2024, changed N/A from a year ago — trailing twelve months through Sep 2024 was $70000.0 (changed N/A YoY), and the annual figure for FY2023 was $26000.0, down 95.58%.
  • Receivables - Other for Q3 2024 was $70000.0 at Corvus Pharmaceuticals, up from $35000.0 in the prior quarter.
  • Over the last five years, Receivables - Other for CRVS hit a ceiling of $588000.0 in Q4 2022 and a floor of $26000.0 in Q4 2023.
  • Median Receivables - Other over the past 3 years was $373000.0 (2022), compared with a mean of $269222.2.
  • Peak annual rise in Receivables - Other hit 15.01% in 2023, while the deepest fall reached 95.58% in 2023.
  • Corvus Pharmaceuticals' Receivables - Other stood at $588000.0 in 2022, then crashed by 95.58% to $26000.0 in 2023, then soared by 169.23% to $70000.0 in 2024.
  • The last three reported values for Receivables - Other were $70000.0 (Q3 2024), $35000.0 (Q2 2024), and $26000.0 (Q1 2024) per Business Quant data.